The most common initial laboratory step in human immunodeficiency virus type 1 (HIV-1) antibody detection is the enzyme inmunoassay (EIA), which, despite its high specificity, has a low positive predictive value when used to screen large populations with a very low prevalence of infection (2) . Thus and Territorial Public Health Laboratory Directors WB criteria (any two of three bands: p24, gp4l, and gpl20/160) (1) . In addition to the displayed reactivity on WB, the first case also showed evidence of p24, p53, gp120, and gp160 and the second case showed evidence of p53, gpl20, and gpl60 on RIPA. The third case had weak reactivity to gpl20 and gpl60, while the final case demonstrated no RIPA reactivity. b One sample from this group was IFA reactive initially but RIPA negative. When retested in duplicate by IFA, the sample was repeatedly negative and was so classified in the final analysis.
All RIPA results for WB-indeterminate samples were negative with the exception of three of the four IFA-positive samples noted above and two other samples which were IFA negative. Of the two IFA-negative samples, the first displayed only nonviral bands on WB and p39 and p53 on RIPA. The second had p51 and p66 WB reactivity and exhibited p24, p39, p53, weak gpl20, and gpl60 on RIPA.
Both RIPAs were repeated with the same results. The four WB-positive samples included as RIPA controls all displayed bands at p24, p39, p53, gpl20, and gpl60.
Considering only those samples classified as either positive or negative by WB, the Fluorognost HIV-1 IFA displayed sensitivity and specificity equivalent to those of the licensed WB when evaluated in a low prevalence population. The IFA was superior to the WB with respect to ease of use and rapidity. Although some technical training was necessary in order to correctly interpret fluorescence patterns, differentiation of positive and negative results was not problematic because of the virtual absence of nonspecific staining.
One drawback of the procedure is the lack of an objective printout, allowing the transcribed test results to become the only permanent record. Photography is one convenient option, however, for laboratories requiring permanent evidence of results. In addition, running samples in duplicate may minimize the effect of errors in interpretation or transcription. Alternatively, the development of an objective image recognition system would help to circumvent this problem. Another limitation is the inability to differentiate the component(s) of the virus to which the serological response is targeted, which may be necessary for certain applications. In conclusion, the Fluorognost HIV-1 IFA is a straightforward, accurate assay which may be useful as a confirmatory test for HIV-1 infection in some laboratory settings.
